Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot trial of YF476 in type I gastric carcinoids
2007-002916-24Phase 2Completed
- Sponsor
- Trio Medicines Ltd
- Start
- Jun 2010
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of netazepide in gastric neuroendocrine neoplasm, atrophic gastritis (AG) and hypergastrinaemia, sponsored by Trio Medicines Ltd. Primary endpoint: Visual assessment of gastric carcinoids. Started Jun 2010; status: completed.
02
Drugs
netazepide
03
Conditions
gastric neuroendocrine neoplasmatrophic gastritis (AG)hypergastrinaemia
Beyond the preview
Go deeper on 2007-002916-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002916-24.